Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jennifer Wheler, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Massachusetts.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
Weill Cornell MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2016 - 2027
Publications & Presentations
PubMed
- 8 citationsPhase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina Anne Piha-Paul, Siqing Fu
Clinical Cancer Research. 2021-03-01 - 18 citationsSafety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki
Clinical Cancer Research. 2020-11-01 - 44 citationsLong-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku
Journal of Hematology & Oncology. 2019-12-30
Press Mentions
Great Danes: Two Nordic Biotechs Name Their Chief Executives; Axel Hoos Bids Adieu to GlaxoSmithKline, Becomes CEO of Small Oncology PlayerJuly 9th, 2021- Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. To Scientific Advisory Board Member and Clinical Consultant RolesJuly 6th, 2021
- Moderna Dips into J&J's Talent Pool for Tal Zaks' Replacement; Jim Mullen Chooses Next Chief Scientist at Editas MedicineJune 18th, 2021
- Join now to see all
